3B Future Health Fund announces new investment in iOnctura
14. Juli 2020 03:00 ET
|
Helsinn Healthcare S.A.
3B Future Health Fund announces new investment in iOnctura MONACO, PRINCIPALITY OF MONACO, July 14, 2020: 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR, today...
Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma
19. September 2019 04:00 ET
|
Helsinn Healthcare S.A.
Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma (MF-CTCL) treatment at the 49th European Society for Dermatological...
Helsinn Investment Fund Announces First Exit
15. Juli 2019 10:05 ET
|
Helsinn Healthcare S.A.
Helsinn Investment Fund Announces First Exit Luxembourg, July 15, 2019 – Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient...
Helsinn Investment Fund: Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology
27. Februar 2019 08:15 ET
|
Helsinn Healthcare S.A.
Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology The Award recognizes Patient Entrepreneurs’ innovations for cancer and cancer...
Helsinn Investment Fund Invests €1 Million in Gain Therapeutics
19. Februar 2019 02:30 ET
|
Helsinn Healthcare S.A.
Helsinn Investment Fund Invests €1 Million in Gain Therapeutics Luxembourg, February 19, 2019: Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of...